A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PH / proportional hazards

[Related PubMed/MEDLINE]
Total Number of Papers: 183
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PH  (>> Co-occurring Abbreviation)
Long Form:   proportional hazards
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer. HNC, HP, KM, LX, NCDB, OC, OP, OS, SEER
2019 An extended proportional hazards model for interval-censored data subject to instantaneous failures. EM
2019 An RCT of atraumatic restorative treatment for older adults: 5 year results. CT
2019 Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. CGGA, GBM, GEO, LASSO, lncRNAs, NCBI, WGCNA
2019 Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. CCCaST, HR-HPV, HRs, TD
2019 Combined test versus logrank/Cox test in 50 randomised trials. RCTs
2019 Comparison of methods for early-readmission prediction in a high-dimensional heterogeneous covariates and time-to-event outcome framework. GB, LR, NN, RF, SCD, SVM
2019 Elevated Risk of Split-Liver Grafts in Adult Liver Transplantation: Statistical Artifact or Nature of the Beast? GS, HRs, LT, SLT, WLT
2019 Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology. HR, PRO
10  2019 No effect of graft size or body mass index on risk of revision after ACL reconstruction using hamstrings autograft. ---
11  2019 Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. PIM
12  2019 Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. DFS
13  2019 Road safety risk factors for non-motorised vehicle users in a Chinese city: an observational study. NMVs
14  2019 [Application of restricted mean survival time in clinical follow-up study]. HR, RMST
15  2018 A nonparametric method for assessment of interactions in a median regression model for analyzing right censored data. PROMMTT
16  2018 An empirical analysis of post-work grocery shopping activity duration using modified accelerated failure time model to differentiate time-dependent and time-independent covariates. AFT, MAFT, NHTS, TAFT, TDM, USDOT
17  2018 An up to 17-year follow-up retrospective analysis of a minimally invasive, flapless approach: 18945 implants in 7783 patients. CSRs, HR
18  2018 Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. AGC, PSM
19  2018 Application of a Frailty Modeling Approach to Correlated Breastfeeding Duration Data. ---
20  2018 Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. HR, RMST
21  2018 Bayesian inference in time-varying additive hazards models with applications to disease mapping. AH
22  2018 BUN as an Independent Predictor of Post-Hospital-Discharge Mortality among Older Veterans. BUN, RCRU
23  2018 Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point. RMST
24  2018 Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population? CCBs, FDC, SePC
25  2018 Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. HR, t-MST
26  2018 How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study. aAbs, FVC, HRCT, ILD, KM
27  2018 How Neighborhood Effects Vary: Childbearing and Fathering among Latino and African American Adolescents. ---
28  2018 Models for Predicting Time to Sputum Conversion Among Multi-Drug Resistant Tuberculosis Patients in Lagos, South-West Nigeria. AIC, HR, MDR-TB
29  2018 Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. AC, ERG, GEM, ICERs, NICE, NMA, OS, PAS, PFS, QALY, STA
30  2018 Patterns of substance use and mortality risk in a cohort of 'hard-to-reach' polysubstance users. CI, HR, LCA, OST
31  2018 Predicting progression to diabetes in islet autoantibody positive children. DAISY, OGTT
32  2018 Risk and outcomes for second primary human papillomavirus-related and -unrelated head and neck malignancy. FG, HNSCC, HPV, SPMs
33  2018 Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. ---
34  2018 Testing causal effects in observational survival data using propensity score matching design. PPW
35  2018 Using threshold regression to analyze survival data from complex surveys: With application to mortality linked NHANES III Phase II genetic data. TR
36  2018 Using time-varying models to estimate post-transplant survival in pediatric liver transplant recipients. TVC
37  2017 A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. ---
38  2017 Application of an Individual-Based Transmission Hazard Model for Estimation of Influenza Vaccine Effectiveness in a Household Cohort. TH, VE
39  2017 Application of Concordance Probability Estimate to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease. AD, ADNI, CPE, MCI
40  2017 Application of random survival forests in understanding the determinants of under-five child mortality in Uganda in the presence of covariates that satisfy the proportional and non-proportional hazards assumption. ---
41  2017 Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models. IPD, NMA
42  2017 Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. aRCC, BSC, HRs, OS, PFS, TKI
43  2017 Comparison of Cox Regression and Parametric Models: Application for Assessment of Survival of Pediatric Cases of Acute Leukemia in Southern Iran AIC, WBC
44  2017 CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer. CCI, HR, NSCLC, PB, PBMC, PCR
45  2017 Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation. AAPs, ACR, BOS, CF, CI, HR, LT, LTRs, Ps
46  2017 Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade] or Conventional Therapy. AEs, CD, CI, HR
47  2017 Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up. KM
48  2017 Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. AGC, OS
49  2017 Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. NLR, OS
50  2017 Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. PS, SSRIs
51  2017 Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models. AFT, AIC, SA, TM
52  2017 The association between gastro-oesophageal reflux disease and subsequent rheumatoid arthritis occurrence: a nested case-control study from Taiwan. GORD, RA
53  2017 The association between physical activity and atrial fibrillation applying the Heaviside function in survival analysis: the Multi-Ethnic Study of Atherosclerosis. AF, hv, PA
54  2017 The effect of health insurance on childhood cancer survival in the United States. CI, SEER
55  2017 Use of acoustic cardiography immediately following electrical cardioversion to predict relapse of atrial fibrillation. AF, ECV, EMAT, LVST
56  2016 A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. CCFR, CI
57  2016 Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. ---
58  2016 Correlating symptoms and their changes with survival in patients with brain metastases. CI, HCPs, OS, QOL, WBRT
59  2016 Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases? KPS, OS, WBRT
60  2016 Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. KM, MM
61  2016 Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. ACR/EULAR, CI, GI, HR, ILD, PAH, PASP, SCORE, SSc, VEDOSS
62  2016 Mediation Analysis with Survival Outcomes: Accelerated Failure Time vs. Proportional Hazards Models. AFT
63  2016 Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. AIx, aPWV, CIMT, CP, CVD, RA
64  2016 Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis. AS, AVR, CI, HR, MACE, NLR
65  2016 Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis. HR, HTA, RCT
66  2016 Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment. MI
67  2016 What Cure Models Can Teach us About Genome-Wide Survival Analysis. ---
68  2015 A Bayesian proportional hazards model for general interval-censored data. ---
69  2015 Adjuvant therapy use among Appalachian breast cancer survivors. AET, AI, MPR
70  2015 An application of propensity score weighting to quantify the causal effect of rectal sexually transmitted infections on incident HIV among men who have sex with men. IPTW, MSM, UAI
71  2015 Analysis of accelerated failure time data with dependent censoring using auxiliary variables via nonparametric multiple imputation. ---
72  2015 Association between trends in clinical variables and outcome in intensive care patients with faecal peritonitis: analysis of the GenOSept cohort. CI, GCS, HR, ICU, SOFA
73  2015 Long-term mortality rates (>8-year) improve as compared to the general and obese population following bariatric surgery. NYS
74  2015 Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. ANN, HRs
75  2015 Re-infection outcomes following one- and two-stage surgical revision of infected hip prosthesis in unselected patients: protocol for a systematic review and an individual participant data meta-analysis. INFORM, IPD
76  2015 Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure. ---
77  2015 The Impact of the Crown-Root Ratio on Survival of Abutment Teeth for Dentures. CI, CRR, RPDs
78  2014 A neural network approach to predicting outcomes in heart failure using cardiopulmonary exercise testing. ANN, CPX, CV, HF, LR
79  2014 Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. AUC
80  2014 Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. MA, MSM
81  2014 Extension of a Cox proportional hazards cure model when cure information is partially known. ---
82  2014 Factors associated with data quality in the routine health information system of Benin. HR, RHIS
83  2014 Impact of the model-building strategy on inference about nonlinear and time-dependent covariate effects in survival analysis. NL, TD
84  2014 Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. CI, HC, HIV, HR, NET-EN, OC
85  2014 Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis. IPD
86  2014 NPHMC: an R-package for estimating sample size of proportional hazards mixture cure model. ---
87  2014 Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. CAP, ICU
88  2014 Stratified Weibull Regression Model for Interval-Censored Data. ---
89  2014 Temporal trends in oropharyngeal cancer treatment and survival: 1998-2009. ChemoRT, RT
90  2014 The consequences of proportional hazards based model selection. ---
91  2013 Acquired hypogammaglobulinemia in HIV-positive subjects after liver transplantation. CI, HGG, HIV, IgG, LT
92  2013 Air pollution and newly diagnostic autism spectrum disorders: a population-based cohort study in Taiwan. ASD, CO, PM10
93  2013 Assessing the fit of parametric cure models. ---
94  2013 Comparison of different parametric proportional hazards models for interval-censored data: a simulation study. HR, MSE
95  2013 Correcting the Results of the Wrong Model: Treatment Effects under Early Detection of Cancer. ---
96  2013 Gray's time-varying coefficients model for posttransplant survival of pediatric liver transplant recipients with a diagnosis of cancer. PC-TVC
97  2013 Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. HP, HR, IA
98  2013 Interval-censored parametric regression survival models and the analysis of longitudinal trials. ---
99  2013 Medication possession ratio predicts antiretroviral regimens persistence in Peru. ART, CVC, LMC, MPR, OPs
100  2013 Omnibus risk assessment via accelerated failure time kernel machine modeling. AFT, KM